Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021